February 4, 2016—Former Turing Pharmaceuticals chief executive Martin Shkreli today invoked his Fifth Amendment right against self-incrimination in declining to answer a House committee’s questions about Turing’s 5,000 percent price increase for a potentially life-saving off-patent medicine lacking competition.
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register. Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)